← Leaderboards
Aditya Bardia
Massachusetts General Hospital
$1,099,974
Attributed
$2,199,947
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $559.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,199,947 · 1
By mechanism
R01$2,199,947 · 1
Top collaborators
- Leif W Ellisen4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Scott Kendall Dessain$5,388,781
- Joren C Madsen$70,026,219
- Maarten Hulsmans$5,811,869
- Ralph Weissleder$110,468,710
- Sara Isabel Pai$12,404,338
Others in their field
Other Rising Stars on “Dna Damage”
- Alexander Kolykhalov · Emory University$8,116,465
- Yun Chen · Johns Hopkins University$3,000,000
- Syed Mukhtar Ahmed · Greenstone Biosciences, Inc.$2,741,939
- Baodong Sun · Duke University$2,697,948
- Akash Patnaik · University Of Chicago$2,630,502
- Kenneth Schultz · Trethera Corporation$2,551,478
Research focus
Dna DamageAntibody-Drug ConjugatesCrispr ScreenBasic ScienceBiological MarkersBiopsyBreast Cancer CellBreast Cancer PatientCancer SubtypesCell ModelCellsChemotherapyClinical BiomarkersClinical DevelopmentClinically RelevantClinical SciencesClinical Trial AnalysisClinical TrialsCombinatorialCombined Modality TherapyComplementComplexCoupledDna Repair
Grant awards (4)
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$559,783
R01 · FY2025 · CA
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$531,794
R01 · FY2024 · CA
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$548,587
R01 · FY2023 · CA
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$559,783
R01 · FY2022 · CA